Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
…, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi… - The lancet …, 2014 - thelancet.com
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with EGFR …
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung …
…, LZ Lin, J Feng, Z Wang, Y Shu, J Shi… - The Lancet …, 2021 - thelancet.com
Background Immunotherapy combined with chemotherapy has been shown to be efficacious
as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without …
as treatment for advanced non-squamous non-small-cell lung cancer (NSCLC) without …
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label …
…, YL Wu, SY Wang, J Hu, W Liu, W Li, JH Shi - The Lancet …, 2018 - thelancet.com
Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …
[PDF][PDF] Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial
…, J Yao, Y Zhang, M Li, J Feng, S Yang, Y Fan, J Shi… - Cancer cell, 2022 - cell.com
Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial.gov: NCT03829969), …
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping …
…, Y Cheng, L Jiang, N Yang, Z Han, J Shi… - The Lancet …, 2021 - thelancet.com
Background Savolitinib is a selective MET tyrosine-kinase inhibitor. We investigated the activity
and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other non…
and safety of savolitinib in patients with pulmonary sarcomatoid carcinoma and other non…
Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized …
…, H Sun, G Wen, Y Ji, M Dvorkin, J Shi, Z Pan, J Shi… - Jama, 2022 - jamanetwork.com
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …
changed the approach to first-line treatment in patients with extensive-stage small cell lung …
Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
…, L Zhang, J Shi, Z Wang, Y Cheng, J He, Y Shi… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in …
…, C Zhu, Z Ma, J Fang, G Chen, J Zhao, A Shi… - The Lancet …, 2022 - thelancet.com
Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …
[HTML][HTML] Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial …
…, HX Huang, Y Chen, GH Dai, JH Shi… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers …
carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers …
[HTML][HTML] AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with …
S Lu, X Dong, H Jian, J Chen, G Chen… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …